The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Tóth, GáborSzöőr, ÁrpádSimon, LászlóYarden, YosefSzöllősi, JánosVereb, György2016-09-282016-09-282016mAbs. - 8 : 7 (2016), p. 1361-1370. -mAbs. - 1942-0862. - 1942-08701942-08621942-0870http://hdl.handle.net/2437/230720The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicityfolyóiratcikkopen access articlehttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM065721OrvostudományokElméleti orvostudományokhttp://www.tandfonline.com/doi/full/10.1080/19420862.2016.1204503Taylor & Francishttp://dx.doi.org/10.1080/19420862.2016.12045032018-05-19